JFrog stock rises as Cantor Fitzgerald maintains Overweight rating after strong Q2
Masimo Corp NASDAQ:MASI Chairman of the Board Michelle Brennan recently purchased shares of the company’s stock in two transactions totaling $30,560. The medical technology company, currently valued at $8.23 billion, has seen its stock rise 7.63% over the past week, according to InvestingPro data.
According to a Form 4 filing with the Securities and Exchange Commission, Brennan bought 100 shares on August 12, 2025, at a price of $150.35, and another 100 shares on August 13, 2025, at $155.25. Following these transactions, Brennan directly owns 7,318 shares of Masimo Corp . InvestingPro analysis shows the stock trading near $151.87, with analyst targets ranging from $170 to $210. Get access to detailed insider trading analysis and 12 additional ProTips with an InvestingPro subscription.
In other recent news, Masimo Corp. reported second-quarter 2025 financial results that exceeded analyst expectations, with sales reaching $370.9 million. This figure surpassed both Stifel’s and consensus estimates, marking a 7.7% year-over-year increase when excluding foreign exchange effects. Despite this positive performance, Needham noted a slowdown in overall revenue growth to 7% on a constant currency basis, down from 10% in the previous quarter. Following these results, Stifel reiterated its Buy rating with a $180.00 price target, while Needham maintained a Hold rating. Jefferies also responded by raising its price target for Masimo to $170.00 from $158.00, citing a lower tariff impact, but kept a Hold rating. Additionally, BTIG reiterated a Buy rating with a $198.00 price target after Apple’s announcement to restore the Blood Oxygen feature on certain Apple Watch models in the U.S. This feature’s return follows a legal dispute with Masimo, resolved through software updates. These developments reflect ongoing adjustments and evaluations by analysts and companies alike.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.